埋め込み犠牲バイオプリンティングによるエンジニアリングされた灌流肝線維化モデルは、剛性駆動型線維症を再現します
Weikang Lv1,2, Tuya Naren1,2, Abdellah Aazmi1,2
1State Key Laboratory of Fluid Power and Mechatronic Systems, Zhejiang University, Hangzhou, China.
Advanced materials (Deerfield Beach, Fla.)
|January 22, 2026
まとめ
この研究では、血管ネットワークを備えた動的な3D肝線維症モデルを開発しました。このモデルは線維症の進行を正確に再現し、肝線維症薬のテストの可能性を示しています。
科学分野:
- 生物医学工学
- 再生医療
- 病態生理学
背景:
- 肝線維症には、細胞外マトリックス(ECM)の硬化と肝星細胞(HSC)の活性化が関与しています。
- 既存のインビトロモデルには、エンジニアリングされた血管系と動的な機械的刺激が欠けています。
研究 の 目的:
- 動的に灌流された3Dインビトロ肝線維症モデルを作成すること。
- マトリックスの剛性と灌流がHSCの活性化と肝細胞機能に与える影響を調査すること。
- 抗線維化療法の評価のためのプラットフォームを確立すること。
主な方法:
- 血管ネットワークを調整可能なヒドロゲルに作成するための埋め込み犠牲バイオプリンティング。
- 3D多細胞培養物の動的灌流。
- さまざまなマトリックス剛性と流体条件下でのHSC活性化と肝細胞機能の評価。
主要な成果:
- マトリックスの剛性は、HSCの活性化と筋線維芽細胞への分化を直接駆動します。
- 動的灌流は、インビボ条件を模倣して、肝細胞の剛性マトリックスへの感受性を高めます。
- 標的阻害は、HSCの活性化を部分的に逆転させ、モデルの肝機能を回復させました。
結論:
- 開発されたモデルは、肝線維症の病態生理学を正確に再現しています。
- このプラットフォームは、肝線維症の創薬スクリーニングと治療評価のための有望なアプローチを提供します。
- 機械的合図と血管系の同時統合は、インビトロ線維症モデリングにとって重要です。
関連する概念動画
Cystic Fibrosis: Pathogenesis
740
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
740
What is Genetic Engineering?
79.8K
Overview
79.8K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
261
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
261
Hepatic Portal System
5.6K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
280
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
280
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
219
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219


